OTCMKTS:AXMP

AXM Pharma Competitors

$0.0002
0.00 (0.00 %)
(As of 04/19/2021 12:00 AM ET)
Add
Compare
Today's Range
$0.00
Now: $0.00
$0.00
50-Day Range N/A
52-Week Range
$0.00
Now: $0.00
$0.04
VolumeN/A
Average Volume27,218 shs
Market Capitalization$81,320.00
P/E RatioN/A
Dividend YieldN/A
Beta-52.62

Competitors

AXM Pharma (OTCMKTS:AXMP) Vs. WDBG, ROSGQ, PZRXQ, OREXQ, MTST, and ALSE

Should you be buying AXMP stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to AXM Pharma, including Woodbrook Group (WDBG), Rosetta Genomics (ROSGQ), PhaseRx (PZRXQ), Orexigen Therapeutics (OREXQ), MetaStat (MTST), and Alseres Pharmaceuticals (ALSE).

AXM Pharma (OTCMKTS:AXMP) and Woodbrook Group (OTCMKTS:WDBG) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, risk, dividends, analyst recommendations, institutional ownership, profitability and earnings.

Earnings and Valuation

This table compares AXM Pharma and Woodbrook Group's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
AXM PharmaN/AN/AN/AN/AN/A
Woodbrook GroupN/AN/AN/AN/AN/A

Risk and Volatility

AXM Pharma has a beta of -52.62, meaning that its share price is 5,362% less volatile than the S&P 500. Comparatively, Woodbrook Group has a beta of -2.24, meaning that its share price is 324% less volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent recommendations and price targets for AXM Pharma and Woodbrook Group, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
AXM Pharma0000N/A
Woodbrook Group0000N/A

Profitability

This table compares AXM Pharma and Woodbrook Group's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
AXM PharmaN/AN/AN/A
Woodbrook GroupN/AN/AN/A

Summary

Woodbrook Group beats AXM Pharma on 1 of the 1 factors compared between the two stocks.

AXM Pharma (OTCMKTS:AXMP) and Rosetta Genomics (OTCMKTS:ROSGQ) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, valuation, dividends, institutional ownership, risk, earnings and analyst recommendations.

Profitability

This table compares AXM Pharma and Rosetta Genomics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
AXM PharmaN/AN/AN/A
Rosetta GenomicsN/AN/AN/A

Earnings and Valuation

This table compares AXM Pharma and Rosetta Genomics' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
AXM PharmaN/AN/AN/AN/AN/A
Rosetta GenomicsN/AN/AN/AN/AN/A

Analyst Recommendations

This is a summary of current ratings for AXM Pharma and Rosetta Genomics, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
AXM Pharma0000N/A
Rosetta Genomics0000N/A

Risk & Volatility

AXM Pharma has a beta of -52.62, meaning that its stock price is 5,362% less volatile than the S&P 500. Comparatively, Rosetta Genomics has a beta of 6.39, meaning that its stock price is 539% more volatile than the S&P 500.

Summary

Rosetta Genomics beats AXM Pharma on 1 of the 1 factors compared between the two stocks.

AXM Pharma (OTCMKTS:AXMP) and PhaseRx (OTCMKTS:PZRXQ) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, dividends, valuation, profitability, risk, analyst recommendations and institutional ownership.

Analyst Recommendations

This is a breakdown of recent ratings and price targets for AXM Pharma and PhaseRx, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
AXM Pharma0000N/A
PhaseRx0000N/A

Profitability

This table compares AXM Pharma and PhaseRx's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
AXM PharmaN/AN/AN/A
PhaseRxN/AN/AN/A

Valuation and Earnings

This table compares AXM Pharma and PhaseRx's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
AXM PharmaN/AN/AN/AN/AN/A
PhaseRxN/AN/AN/AN/AN/A

Volatility & Risk

AXM Pharma has a beta of -52.62, meaning that its stock price is 5,362% less volatile than the S&P 500. Comparatively, PhaseRx has a beta of -0.86, meaning that its stock price is 186% less volatile than the S&P 500.

Summary

PhaseRx beats AXM Pharma on 1 of the 1 factors compared between the two stocks.

AXM Pharma (OTCMKTS:AXMP) and Orexigen Therapeutics (OTCMKTS:OREXQ) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, risk, profitability, institutional ownership, earnings, analyst recommendations and valuation.

Volatility & Risk

AXM Pharma has a beta of -52.62, suggesting that its share price is 5,362% less volatile than the S&P 500. Comparatively, Orexigen Therapeutics has a beta of 4.98, suggesting that its share price is 398% more volatile than the S&P 500.

Valuation & Earnings

This table compares AXM Pharma and Orexigen Therapeutics' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
AXM PharmaN/AN/AN/AN/AN/A
Orexigen Therapeutics$33.71 million0.00$-24,520,000.00N/AN/A

AXM Pharma has higher earnings, but lower revenue than Orexigen Therapeutics.

Profitability

This table compares AXM Pharma and Orexigen Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
AXM PharmaN/AN/AN/A
Orexigen TherapeuticsN/AN/AN/A

Analyst Recommendations

This is a breakdown of current recommendations and price targets for AXM Pharma and Orexigen Therapeutics, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
AXM Pharma0000N/A
Orexigen Therapeutics0000N/A

Summary

Orexigen Therapeutics beats AXM Pharma on 2 of the 2 factors compared between the two stocks.

MetaStat (OTCMKTS:MTST) and AXM Pharma (OTCMKTS:AXMP) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, profitability, dividends, valuation, risk, earnings and institutional ownership.

Volatility and Risk

MetaStat has a beta of -4.21, suggesting that its stock price is 521% less volatile than the S&P 500. Comparatively, AXM Pharma has a beta of -52.62, suggesting that its stock price is 5,362% less volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for MetaStat and AXM Pharma, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
MetaStat0000N/A
AXM Pharma0000N/A

Valuation & Earnings

This table compares MetaStat and AXM Pharma's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
MetaStat$20,000.004.15$-3,180,000.00N/AN/A
AXM PharmaN/AN/AN/AN/AN/A

AXM Pharma has lower revenue, but higher earnings than MetaStat.

Profitability

This table compares MetaStat and AXM Pharma's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
MetaStatN/AN/AN/A
AXM PharmaN/AN/AN/A

Summary

MetaStat beats AXM Pharma on 2 of the 2 factors compared between the two stocks.

AXM Pharma (OTCMKTS:AXMP) and Alseres Pharmaceuticals (OTCMKTS:ALSE) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, valuation, earnings, dividends, institutional ownership, risk and profitability.

Earnings & Valuation

This table compares AXM Pharma and Alseres Pharmaceuticals' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
AXM PharmaN/AN/AN/AN/AN/A
Alseres PharmaceuticalsN/AN/AN/AN/AN/A

Volatility and Risk

AXM Pharma has a beta of -52.62, suggesting that its stock price is 5,362% less volatile than the S&P 500. Comparatively, Alseres Pharmaceuticals has a beta of -0.06, suggesting that its stock price is 106% less volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent ratings for AXM Pharma and Alseres Pharmaceuticals, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
AXM Pharma0000N/A
Alseres Pharmaceuticals0000N/A

Profitability

This table compares AXM Pharma and Alseres Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
AXM PharmaN/AN/AN/A
Alseres PharmaceuticalsN/AN/AN/A

Summary

Alseres Pharmaceuticals beats AXM Pharma on 1 of the 1 factors compared between the two stocks.


AXM Pharma Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
WDBG
Woodbrook Group
0.0$1.60flat$224,000.00N/A0.00
ROSGQ
Rosetta Genomics
0.0$0.10flat$183,000.00N/A0.00Gap Down
PZRXQ
PhaseRx
0.2$0.02flat$175,000.00N/A0.00
OREXQ
Orexigen Therapeutics
0.4$0.01flat$100,000.00$33.71 million0.00Gap Up
MetaStat logo
MTST
MetaStat
0.0$0.01flat$82,000.00$20,000.000.00
ALSE
Alseres Pharmaceuticals
0.0$6.00flat$36,000.00N/A0.00
BOPH
Bohai Pharmaceuticals Group
0.5$0.00flat$20,000.00N/A0.00
Immune Therapeutics logo
IMUN
Immune Therapeutics
0.6$0.01flat$7,000.00$110,000.000.00Gap Up
Acusphere logo
ACUS
Acusphere
0.0$0.04flat$0.00N/A0.00Gap Down
Affymax logo
AFFY
Affymax
0.6$0.10flat$0.00N/A0.00Gap Up
AOBI
American Oriental Bioengineering
0.4$1.50flat$0.00N/A0.00
ARYX
ARYx Therapeutics
0.0$0.01flat$0.00N/A0.00
AHROQ
AtheroNova
0.0$0.01flat$0.00N/A0.00
CBPI
China Botanic Pharmaceutical
0.0$0.07flat$0.00N/A0.00
China Dongsheng International logo
CDSG
China Dongsheng International
0.3$0.01flat$0.00N/A0.00
China Health Industries logo
CHHE
China Health Industries
0.4$0.49flat$0.00$9.93 million8.13
DDXSQ
Diadexus
0.0N/AN/A$0.00N/A0.00
ERBA
ERBA Diagnostics
0.8$0.04flat$0.00N/A0.00
FTCY
Global Future City
0.5$0.00flat$0.00N/A0.00
GLSI
Greenwich LifeSciences
2.0$32.22flat$0.00N/A0.00Decrease in Short Interest
Gap Up
HRBR
Harbor Diversified
0.0$1.28flat$0.00$263.61 million0.00
IPAH
Interpharm
0.2$0.00flat$0.00N/A0.00
IRBS
IR Biosciences
0.0$0.00flat$0.00N/A0.00High Trading Volume
MBVXQ
MabVax Therapeutics
0.0$0.02flat$0.00N/A0.00Gap Up
MYRX
Myrexis
0.5$0.06flat$0.00N/A0.00Gap Up
NNBP
Nanobac Pharmaceuticals
0.0$0.00flat$0.00N/A0.00Gap Down
PARD
Poniard Pharmaceuticals
0.5$0.05flat$0.00N/A0.00Gap Up
SGTI
Shengtai Pharmaceutical
0.2$0.02flat$0.00N/A0.00
SKBI
Skystar Bio-Pharmaceutical
0.5$0.00flat$0.00N/A0.00
SUWN
Sunwin Stevia International
0.5$0.06flat$0.00$26.09 million0.00Gap Down
Sycamore Entertainment Group logo
SEGI
Sycamore Entertainment Group
0.3$0.04flat$0.00N/A0.00
SYNI
Synvista Therapeutics
0.0$0.00flat$0.00N/A0.00
Targeted Medical Pharma logo
TRGM
Targeted Medical Pharma
0.8$0.07flat$0.00N/A0.00
TPIY
Tianyin Pharmaceutical
0.6$0.00flat$0.00N/A0.00High Trading Volume
Tibet Pharmaceuticals logo
TBET
Tibet Pharmaceuticals
0.0$0.03flat$0.00N/A0.00Gap Down
VOQP
VioQuest Pharmaceuticals
0.0$0.02flat$0.00N/A0.00
This page was last updated on 4/20/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.